' '
Deutsch | English    

Forschungsdatenbank PMU-SQQUID

Targeting interleukin-6 to treat neuromyelitis optica spectrum disorders: Implications from immunology, the FcRn pathway and clinical experience.
Sellner, J; Sitte, HH; Rommer, PS
DRUG DISCOV TODAY. 2021; 26(7): 1591-1601.
├ťbersichtsarbeiten

PMU-Autor/inn/en


Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is a rare disease of the central nervous system (CNS) that is associated with poor outcomes for patients. Until recently, when complement inhibitors were approved, there was no approved therapy. Most recently, clinical trials of interleukin-6 (IL-6) blockade showed a therapeutic benefit for NMOSD. In this review, we introduce the immunological basis of IL-6 blockade in NMOSD and summarize current knowledge about the clinical use of the IL-6 receptor inhibitors tocilizumab and satralizumab. The aim of extending the half-life of monoclonal antibodies (mAbs) has been actualized by successful clinical translation for Satralizumab, achieved via the neonatal Fc receptor (FcRn) pathway. The basic principles of FcRn are highlighted in this review together with the potential therapeutic benefits of this emerging technology.


Find related publications in this database (Keywords)

Neuromyelitis optica
NMOSD
Interleukin-6
Monoclonal antibody
Disease-modifying therapy
Neonatal pathway
Aquaporin antibody